Global Rheumatology Therapeutics Market Ready To Boost And Reach USD 50.9 Billion by 2022


(MENAFNEditorial) Some of the major players active in the rheumatology therapeutics market are Pfizer, Inc., AbbVie, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Janssen Biotech, Inc., Amgen, Inc., Genentech, Inc., Novartis AG, Sanofi, and Takeda Pharmaceutical among others. These players are set to power the rheumatology therapeutics market in the near future.

According to the experts at Zion Market Research, the global rheumatology therapeutics market was capitalized at almost USD 44.18 Billion in 2017 and is likely to cross almost USD 50.9 Billion by end of 2022, developing at a CAGR of 2.9 % from 2016 to 2022.

Browse the full "Rheumatology Therapeutics Market by Disease Type (Rheumatoid Arthritis, Osteoarthritis, Lupus, Gout, Ankylosing spondylitis and other), Drug Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Analgesics, Disease Modifying Anti-Rheumatic Drugs (DMARDs), Corticosteroids and Others), Distribution Channel (Retail Pharmacy, Online Pharmacy, Hospitals): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 2022.: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 2022." report at https://www.zionmarketresearch.com/report/rheumatology-therapeutics-market

Increasing Burden Of Rheumatic Diseases All Over The Globe Boosting The Development Of Rheumatology Therapeutics Market

The increasing burden of rheumatic diseases all over the globe is boosting the development of rheumatology therapeutics market. A broad number of drugs and biosimilars in the pipeline are powering the development of rheumatology therapeutics market. On the other hand, stringent rules & regulations and high capital investments in drug development are hindering the development of rheumatology therapeutics market. Technologically advanced goods such as biosimilars & biologics are likely to present lucrative growth avenues in future in the rheumatology therapeutics market. For example, in September 2018, Ronald F van Vollenhoven and associates reported in Lancet that UST (ustekinumab)—an interleukin-12 and -23 inhibitor—when added to normal therapy in SLE (systemic lupus erythematosus) patients, was claimed to be superior at enhancing laboratory parameters and clinical efficacy, boosting the rheumatology therapeutics market.

Based on disease type, the global rheumatology therapeutics market is classified into osteoarthritis, rheumatoid arthritis, gout, lupus, and ankylosing spondylitis among other. Rheumatoid arthritis disease has high occurrence rates in comparison to any other disease and adds up for the lion's share in global rheumatology therapeutics market. Based on drug type, the rheumatology therapeutics market is divided into analgesics, non-steroidal anti-inflammatory drugs, corticosteroids, disease modifying anti-rheumatic drugs, and other. Disease modifying anti-rheumatic drugs segment ruled the rheumatology therapeutics market in 2016 due to their elevated employment in the early phase of treatment. The distribution channel sector of rheumatology therapeutics comprises online pharmacy, retail pharmacy, and hospitals.

North America To Rule The Global Rheumatology Therapeutics Market Due To Soaring Capital Investments In The Pharma Industry And Elevated Geriatric Population

The global rheumatology therapeutics market was ruled by North America and it grabbed an utmost share of total income generated in the rheumatology therapeutics market in 2016. The development in this area is credited to the soaring capital investments in the pharma industry and elevated geriatric population. Europe is another leading are for rheumatology therapeutics market after North America. Advanced healthcare infrastructure and increasing occurrences of rheumatoid diseases are responsible for the growth of the rheumatology therapeutics market in this region.

The global rheumatology therapeutics market is segmented as follows:

By Disease

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Lupus
  • Gout

By Drug

  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Analgesics
  • Disease Modifying Anti-Rheumatic Drugs (DMARDs)
  • Corticosteroids
  • Others

By Distribution Channel

  • Retail Pharmacy
  • Online Pharmacy
  • Hospitals
  • Other

By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email:
Website: https://www.zionmarketresearch.com

MENAFN1310201800703707ID1097562968


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.